CILENGITIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME AND UNMETHYLATED MGMT GENE PROMOTER: SAFETY RUN-IN RESULTS FROM A RANDOMIZED, CONTROLLED, PHASE II STUDY (CORE)

被引：0
|
作者：
Mikkelsen, T. [1 ]
Nabors, L. B. [2 ]
Fink, K. [3 ]
Chan, M. [4 ]
Trusheim, J. [5 ]
Raval, S. [6 ,10 ]
Hicking, C. [7 ]
Henslee-Downey, J. [9 ]
Picard, M. [7 ]
Reardon, D. [8 ]
机构：
[1] Henry Ford Hlth Syst, Detroit, MI USA
[2] Univ Alabama, Neurooncol Program, Birmingham, AL USA
[3] Baylor Univ, Med Ctr, Dallas, TX USA
[4] Wake Forest Univ Hlth Sci, Winston Salem, NC USA
[5] Virginia Piper Canc Inst, Minneapolis, MN USA
[6] Monmouth Med Ctr, Long Branch, NJ USA
[7] Merck KGaA, Darmstadt, Germany
[8] Duke Univ, Med Ctr, Preston Robert Tisch Brain Tumour Ctr, Durham, NC USA
[9] EMD Serono Inc, Rockland, MA USA
[10] Garden State Neurol & Neurooncol, Long Branch, NJ USA
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：173 / 173
页数：1
相关论文
共 50 条
  • [1] CILENGITIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME AND UNMETHYLATED MGMT GENE PROMOTER: SAFETY RUN-IN RESULTS FROM A RANDOMIZED CONTROLLED PHASE II STUDY (CORE)
    Nabors, Burt
    Fink, Karen
    Mikkelsen, Tom
    Chan, Michael
    Trusheim, John
    Raval, Sumul
    Hicking, Christine
    Henslee-Downey, Jean
    Picard, Martin
    Reardon, David
    NEURO-ONCOLOGY, 2010, 12 : 75 - 75
  • [2] Cilengitide in patients with newly diagnosed glioblastoma multiforme and unmethylated MGMT gene promoter: Protocol of a multicenter, randomized, open-label, controlled phase II study
    Nabors, L. B.
    Fink, K.
    Reardon, D. A.
    Lesser, G. J.
    Trusheim, J.
    Raval, S. N.
    Hicking, C.
    Picard, M.
    Mikkelsen, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study
    Nabors, L. Burt
    Fink, Karen L.
    Mikkelsen, Tom
    Grujicic, Danica
    Tarnawski, Rafal
    Nam, Do Hyun
    Mazurkiewicz, Maria
    Salacz, Michael
    Ashby, Lynn
    Zagonel, Vittorina
    Depenni, Roberta
    Perry, James R.
    Hicking, Christine
    Picard, Martin
    Hegi, Monika E.
    Lhermitte, Benoit
    Reardon, David A.
    NEURO-ONCOLOGY, 2015, 17 (05) : 708 - 717
  • [4] CILENGITIDE IN COMBINATION WITH STANDARD TREATMENT FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WITH UNMETHYLATED O6-METHYLGUANINE- DNA METHYLTRANSFERASE (MGMT) GENE PROMOTER: KEY RESULTS OF THE OPEN-LABEL, CONTROLLED, RANDOMIZED PHASE II CORE STUDY
    Nabors, Louis Burt
    Fink, Karen L.
    Mikkelsen, Tom
    Grujicic, Dan
    Tarnawski, Rafal
    Nam, Do-Hyun
    Mazurkiewicz, Maria
    Salacz, Michael
    Ashby, Lynn
    Thurzo, Laszlo
    Zagonel, Vittorina
    Depenni, Roberta
    Perry, James R.
    Henslee-Downey, Jean
    Picard, Martin
    Reardon, David A.
    NEURO-ONCOLOGY, 2013, 15 : 80 - 80
  • [5] A Safety Run-In and Randomized Phase 2 Study of Cilengitide Combined With Chemoradiation for Newly Diagnosed Glioblastoma (NABTT 0306)
    Nabors, L. Burt
    Mikkelsen, Thomas
    Hegi, Monika E.
    Ye, Xiaubu
    Batchelor, Tracy
    Lesser, Glenn
    Peereboom, David
    Rosenfeld, Myrna R.
    Olsen, Jeff
    Brem, Steve
    Fisher, Joy D.
    Grossman, Stuart A.
    CANCER, 2012, 118 (22) : 5601 - 5607
  • [6] A randomized phase II study investigating cilengitide added to standard chemoradiotherapy in patients with newly diagnosed glioblastoma with unmethylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter: Initial report of the CORE study
    Nabors, L.
    Fink, K.
    Mikkelsen, T.
    Grujicic, D.
    Tarnawski, R.
    Nam, D.
    Perry, J.
    Markivskyy, A.
    Picard, M.
    Reardon, D.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S17 - S18
  • [7] Pharmacokinetics and pharmacodynamics of paxalisib in newly diagnosed glioblastoma patients with unmethylated MGMT promoter status: Final phase II study results
    Wen, P.
    De Groot, J. F.
    Battiste, J.
    Goldlust, S.
    Damek, D.
    Ellingson, B.
    Garner, J.
    Friend, J.
    Simpson, J.
    Olivero, A.
    Cloughesy, T.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S667 - S667
  • [8] Paxalisib in patients with newly diagnosed glioblastoma with unmethylated MGMT promoter status: Final phase 2 study results
    Wen, Patrick Y.
    De Groot, John Frederick
    Battiste, James
    Goldlust, Samuel A.
    Garner, James Stuart
    Friend, John
    Simpson, Jeremy Andrew
    Damek, Denise
    Olivero, Alan
    Cloughesy, Timothy Francis
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] Anti-telomerase vaccine in patients with newly diagnosed, unmethylated MGMT glioblastoma: A phase II study
    Carpentier, Antoine F.
    Verlut, Clotilde
    Ghiringhelli, Francois
    Bronnimann, Charlotte
    Ursu, Renata
    Fumet, Jean David
    Gherga, Elisabeta
    Lefort, Felix
    Belin, Catherine
    Vernerey, Dewi
    Hervieu, Alice
    Laheurte, Caroline
    Meurisse, Aurelia
    Jacquin, Marion
    Malfroy, Marine
    Fagnoni-Legat, Christine
    Lehmann-Che, Jacqueline
    Boullerot, Laura
    Cuzzubbo, Stefania
    Adotevi, Olivier
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] PHASE II STUDY OF AZELIRAGON IN COMBINATION WITH RADIATION THERAPY IN NEWLY DIAGNOSED PATIENTS WITH MGMT-UNMETHYLATED GLIOBLASTOMA
    Huang, Jiayi
    Ahluwalia, Manmeet
    Boockvar, John
    Batiste, James
    Jaboin, Jerry
    Thotala, Dinesh
    Halasz, Lia
    Rammohan, Nikhil
    Ney, Douglas
    Malani, Rachna
    Chinnaiyan, Prakash
    Kotecha, Rupesh R.
    Mehta, Minesh
    Marcus, Stephen
    NEURO-ONCOLOGY, 2024, 26
12345